Abstract
This study investigated the role of vascular endothelial growth factor (VEGF) in 18 patients with first-episode schizophrenia (FES) and 19 healthy controls and the effect of risperidone monotherapy on plasma VEGF levels. The plasma VEGF levels were measured at baseline and after four weeks of risperidone treatment. We found no difference in baseline VEGF levels between the groups and no change in VEGF levels after risperidone treatment. No correlation was found between VEGF levels and symptom severity. Our findings suggest that VEGF may not serve as a distinguishing biomarker in FES or be directly influenced by risperidone.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
